Cabaletta Bio (NASDAQ:CABA) Insider Gwendolyn Binder Acquires 11,312 Shares of Stock

Cabaletta Bio, Inc. (NASDAQ:CABA) insider Gwendolyn Binder acquired 11,312 shares of the company’s stock in a transaction on Wednesday, January 21st. The shares were acquired at an average cost of $2.19 per share, for a total transaction of $24,773.28. Following the completion of the acquisition, the insider owned 31,312 shares of the company’s stock, valued at approximately $68,573.28. The trade was a 56.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Cabaletta Bio Stock Performance

Shares of NASDAQ CABA opened at $2.34 on Thursday. The stock has a fifty day moving average of $2.29 and a 200-day moving average of $2.11. The stock has a market cap of $225.25 million, a PE ratio of -0.92 and a beta of 3.25. Cabaletta Bio, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $3.67.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. On average, sell-side analysts predict that Cabaletta Bio, Inc. will post -2.34 EPS for the current year.

Key Stories Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares at an average $2.24/share (≈$100,800), increasing his stake to ~1.03M shares — a meaningful insider buy from the company’s top executive. SEC filing
• Positive Sentiment: Director Mark Simon acquired 11,061 shares at ~$2.28/share (~$25.2K), an 8.12% increase in his holding to ~147K shares. SEC filing
• Positive Sentiment: General Counsel Michael Gerard bought 6,600 shares at $2.27/share (~$15K), initiating a new disclosed holding. SEC filing
• Positive Sentiment: Other insiders (director Shawn Tomasello, insider Steve Gavel, Gwendolyn Binder, David J. Chang) executed purchases ranging ~8.8K–22.7K shares at ~$2.19–$2.27 each, many representing large % increases in their positions — broad insider participation suggests aligned bullish views across management and the board. SEC filings
• Positive Sentiment: Report: Cabaletta is accelerating its autoimmune CAR‑T program and is targeting a 2027 FDA filing — a multi‑year development path but one that, if achieved, would be value‑creating. Cabaletta targets 2027 FDA filing as autoimmune CAR-T push accelerates

Wall Street Analysts Forecast Growth

Several research analysts have commented on CABA shares. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a research note on Friday, October 10th. Jefferies Financial Group assumed coverage on shares of Cabaletta Bio in a research note on Friday, October 10th. They issued a “buy” rating and a $14.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald boosted their price objective on Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cabaletta Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

Hedge Funds Weigh In On Cabaletta Bio

A number of institutional investors have recently added to or reduced their stakes in CABA. CRA Financial Services LLC lifted its position in Cabaletta Bio by 36.4% during the third quarter. CRA Financial Services LLC now owns 15,000 shares of the company’s stock valued at $35,000 after buying an additional 4,000 shares during the period. Jones Financial Companies Lllp bought a new position in shares of Cabaletta Bio during the third quarter valued at approximately $47,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Cabaletta Bio during the second quarter valued at approximately $32,000. SG Americas Securities LLC increased its position in Cabaletta Bio by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 30,629 shares of the company’s stock valued at $67,000 after buying an additional 9,365 shares in the last quarter. Finally, Comerica Bank increased its holdings in shares of Cabaletta Bio by 2,292.1% during the first quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after acquiring an additional 39,860 shares in the last quarter.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.